Skip to main content
Home

Search form

  • ABOUT US
    • ECFS Society Details
      • Society Information
      • Applications for Support
    • ECFS Membership
      • Membership Subscription
      • Membership Demographics
    • Other Information
      • Latest News
      • Job Opportunities
      • Grants and Programmes
      • Links
  • RESEARCH
    • ECFS Projects
      • ECFS Clinical Trials Network
      • ECFS Patient Registry
    • ECFS Working Groups
      • Diagnostic Network
      • Exercise
      • Neonatal Screening
      • Fungal Pathogens
      • Pulmonary Exacerbation
    • Special Projects
      • ECFS / CF Europe Post-Doctoral Research Fellowship
      • CFQ-R questionnaire and CF candidates for lung transplant
      • EU funded projects
      • MucoFong International Project
      • Complete CFTR gene mutation analysis in European patients with Cystic Fibrosis
    • Past Working Groups
      • Cystic Fibrosis Molecular and Cell Biology and Physiology Basic Science
      • ECFS Gene Modifier Working Group
      • ECFS Non Tuberculous Mycobacteria Working Group
  • CARE
    • ECFS Standards Of Care
    • ECFS Working Groups
      • Exercise
      • Diagnostic Network
      • Neonatal Screening
      • Mental Health
      • Fungal Pathogens
      • Pulmonary Exacerbation
      • Telehealth
    • Allied Health Professionals
      • ECFS Nursing Special interest Group
      • European CF Pharmacy Group
      • European Cystic Fibrosis Nutrition Group
      • European Psychosocial Special Interest Group
      • ECFS Physiotherapy Special Interest International Group
  • EDUCATION
  • CONFERENCES & EVENTS
    • European Cystic Fibrosis Conference
    • ECFS Basic Science Conference
    • Related events
    • Past ECFS conferences
  • PUBLICATIONS
    • About Publications
      • The Journal of Cystic Fibrosis
      • ECFS Newsletter
      • ECFS Book
      • ERS Monograph
    • Resources
      • Search All Resources
      • CF Research News
      • Consensus Reports
      • ECFS Guidelines
      • Free Access Articles
      • CF Literature
  • MEMBERSHIP
  • LOG IN

Other Guidelines

Changes in weight and how much you eat after starting triple modulator therapy in adults with cystic fibrosis

  • Read more about Changes in weight and how much you eat after starting triple modulator therapy in adults with cystic fibrosis

Anxiety and Depression Symptom Patterns over 6 years in one Pediatric CF Center

  • Read more about Anxiety and Depression Symptom Patterns over 6 years in one Pediatric CF Center

Weight A Minute: Exploring the effect on total weight, fat and fat-free weight after the initiation of Elexacaftor/ Tezacaftor/ Ivacaftor in adults with CF

  • Read more about Weight A Minute: Exploring the effect on total weight, fat and fat-free weight after the initiation of Elexacaftor/ Tezacaftor/ Ivacaftor in adults with CF

Elexacaftor/Tezacaftor/Ivacaftor improves CFTR activity and pulmonary function in Cystic Fibrosis Patients carrying the N1303K Mutation

  • Read more about Elexacaftor/Tezacaftor/Ivacaftor improves CFTR activity and pulmonary function in Cystic Fibrosis Patients carrying the N1303K Mutation

Effects of elexacaftor/tezacaftor/ivacaftor on liver tests in cystic fibrosis

  • Read more about Effects of elexacaftor/tezacaftor/ivacaftor on liver tests in cystic fibrosis

People with CF face high costs of CF care which have implications for debt, access to health care, adequate food, and other necessities of life.

  • Read more about People with CF face high costs of CF care which have implications for debt, access to health care, adequate food, and other necessities of life.

Airway infection increases Pseudomonas aeruginosa acquisition

  • Read more about Airway infection increases Pseudomonas aeruginosa acquisition

What happens to muscle, fat and body mass index between 8 and 18 years of age in children with cystic fibrosis

  • Read more about What happens to muscle, fat and body mass index between 8 and 18 years of age in children with cystic fibrosis

Elexacaftor/Tezacaftor/Ivacaftor improves CFTR activity and pulmonary function in Cystic Fibrosis Patients carrying the N1303K Mutation

  • Read more about Elexacaftor/Tezacaftor/Ivacaftor improves CFTR activity and pulmonary function in Cystic Fibrosis Patients carrying the N1303K Mutation

A mobile app for self-management of CF and improved patient-centred care

  • Read more about A mobile app for self-management of CF and improved patient-centred care
  • first
  • previous
  • …
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • …
  • next
  • last
Terms & Conditions Privacy policy  Accessibility Sitemap Contact 
© EUROPEAN CYSTIC FIBROSIS SOCIETY 2025. All rights reserved. Website by VidaVia (link is external)
European Cystic Fibrosis Society (ECFS)